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Introduction
The decision to terminate the Women’s Health Initiative
(WHI) study, a randomized controlled trial (RCT) of
hormone replacement therapy, and the public anxiety
caused by the subsequent media publicity have put the
hierarchy of evidence in epidemiology in the spotlight.
Clinical medicine including rheumatology has also some-
times witnessed similar contradictions between the results
of RCTs and observational studies. For example, RCTs
indicated an efficacy for auranofin greatly exceeding that
observed in observational studies or in clinical practice
[1–3]. A meta-analysis of RCTs in 1990 [4] concluded
that the efficacy of injectable gold salts, penicillamine and
sulfasalazine did not differ from that of methotrexate in
patients with rheumatoid arthritis. By contrast, and more in
line with clinical experience, observational research
reports indicated that courses of methotrexate were con-
tinued for much longer time than other agents, suggesting
a better experience with this drug. Currently penicillamine
and auranofin are almost never used for treating rheuma-
toid arthritis. Thus, some prominent clinical trials published
in well-respected journals reached conclusions that were
not validated in clinical practice.
The tools of observational epidemiology become critical
‘when the perfectionist demands of clinical trials crash
against the shoals of real-world conditions’ [5]. There can
never be an RCT for every single clinical question. Many
important observations over the past two decades in
rheumatology would not have been possible without
observational research. Recognition of outcomes such as
work disability, functional disability, and increased mortal-
ity rates in rheumatoid arthritis required long-term observa-
tional studies. More recently, the success of ‘inverted
pyramid’ strategies for patients with rheumatoid arthritis
has been documented [6]. The problem of gastrointestinal
bleeding, ulcers, and obstruction associated with non-
steroidal anti-inflammatory drugs was not apparent from
RCTs but rather from long-term observational databases.
Furthermore, the wide differences in toxicity between the
non-steroidal anti-inflammatory drugs themselves were not
demonstrated by the multiple RCTs.
Agreement between observational studies and RCTs
increases our confidence that the effect of a drug is real
[7]. The problems arise when there is discordance. Here
we attempt to suggest reasons that results from RCTs
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might sometimes differ from clinical practice and observa-
tional studies. The scientific rigor of the process of experi-
mentation, the unflinching focus on the question ‘Is drug A
performing better than the comparator?’ comes with a
price, often poor generalizability. Results are not necessar-
ily similar over the long term, in less selected populations
or after ‘dose creeps’ have moved the doses used in clini-
cal practice far from those of the RCT. The seldom-enu-
merated limitations of RCTs (Table 1) are such that
short-term efficacy data from clinical trials must be supple-
mented with analyses of long-term effectiveness using
observational research databases.
The Food and Drug Administration of the USA has intro-
duced a requirement for post-marketing surveillance of
newer drugs including biological agents; these are now
being pursued by pharmaceutical industry, which has set
up several surveillance databanks. In addition to monitor-
ing for safety, these databanks collect information that has
potential business applications. Such information includes
drug dosage and drug switching patterns of the manufac-
turer’s drugs as well as those of their competitors. It is not
known to what extent these data are put to use for drug
marketing. In addition, many of these databanks might not
adhere to recommended standards for longitudinal studies
[8,9].
Limitations of observational studies
One of the biggest criticisms of observational databanks
results from potential bias in assignment of treatment by a
physician. ‘Confounding by indication’ means that certain
treatments are preferentially given to sicker patients and
certain treatments preferentially to healthier patients. Thus,
it is not uncommon for aspirin to be associated with
increased risk for acute myocardial infarction in observa-
tional studies, because it is prescribed to those with a
higher risk for coronary events. Many studies use statisti-
cal methods such as propensity scores that purportedly
adjust for such bias. In this method of adjustment, the
probability (propensity) of each patient’s receiving a treat-
ment is calculated on the basis of the collected informa-
tion such as age, gender, and education. This propensity
score can then be used for ‘adjusting’ for the effect of
confounders by matching, by stratification, and by regres-
sion models. However, propensity scores might not adjust
for unobserved covariates [10], especially if such covari-
ates are not correlated with observed covariates. Further-
more, once data are collected, there is no fully satisfactory
means to determine whether the adjustment is proportion-
ate to the magnitude of the underlying confounding effect.
The second set of potential limitations results from patient
self-selection. Very few databank studies report the
number and characteristics of patients who were invited to
be a part of the study but who eventually declined,
whereas a lack of similar information in a report of an RCT
might be considered unacceptable. Selection might also
occur if patients or physicians receive financial incentives
to complete questionnaires or enroll in studies (such as
those studies sponsored by pharmaceutical industry).
Another major issue is attrition or subject drop-out. Non-
random drop-outs from studies are inevitable, and selec-
tive attrition of subjects can result in biased (often
exaggerated) estimates of drug effectiveness. Very few
databanks have formally reported the issue of attrition
among their subject population.
The third set of limitations involves measurement of out-
comes. Although questionnaire-based self-reports of out-
comes might be considered to be as informative as
Table 1
Some limitations of randomized controlled trials
Patient selection limited by inclusion and exclusion criteria
Short time frame, as long-term clinical trials are ethically or logistically not possible
Differential drop-out patterns between arms of the trial
Statistically significant results might not necessarily be clinically significant, and vice versa
Surrogate markers such as joint tenderness might be suboptimal indicators of prevention of severe long-term outcomes such as radiographic
destruction and work disability
Chance (bad luck) can lead to unbalanced groups
Inflexible dosage schedules
‘Dose creep’ from trial to clinic, rendering trial obsolete
Inability to identify rare adverse events
Hawthorne effect: patients in a study alter their behavior when they are told to be in the study
Design bias: randomized controlled trials might be designed to maximize the probability of a particular outcome, namely the superiority of the new drug43
physician-based measures [11], the practicalities of mea-
surement, analysis, and interpretation raise several issues.
Longitudinal observational studies typically measure out-
comes in specified intervals of 3, 6, or 12 months.
Because the start and end of a drug course do not neces-
sarily correspond to the measurement dates, difficulties
can arise in correlating outcomes with drug courses. Thus,
patient outcomes from drug courses shorter than the inter-
val between measurements tend to be selectively lost.
Because early termination of drug courses might indicate
failure due to toxicity or inefficacy, the loss of information
from these drug courses has the potential to bias the
effectiveness estimates upwards. Besides, the absence of
a ‘washout period’ in observational studies makes it diffi-
cult to disentangle the effects of current therapies from
the residual effects of past therapies, particularly when the
clinical half-life is varied and long [12].
Strengthening observational databanks
Observational studies need to be protocol-driven, with
prospective data collection including the Health Assess-
ment Questionnaire (HAQ) or its variants, short form 36
(SF-36), or a similar instrument at regular intervals [8,9].
Where drop-outs occur, careful documentation of the
details (change in address, refusal, worsening health, and
so on) of such losses is required. Rigor in data collection
in observational databanks can and should be equivalent
to that of RCTs.
We believe the criticism of unobserved bias has been
overused. It should not be applied uncritically unless a
specific, plausible unmeasured confounder is specified.
Such potential confounders need to meet both of the two
criteria of confounding, namely (1) association with
outcome and (2) no association with the observed vari-
ables used for statistical adjustment. We agree with
Moses [13] that it is important for the treating physician to
record why the patient is being given the therapy selected.
This information should be a powerful adjustment variable;
‘arranging to collect it will call for imaginative thinking,
experimentation, and patience, but it is an idea deserving
much effort’ [13].
Several steps could be taken within the existing framework
for clinical research that can go a long way in improving
the use of databanks. Many of the problems with observa-
tional studies can be minimized with careful planning in
advance of the study. Ideally the subjects in longitudinal
databanks should be truly representative of the population.
Short of that, a databank should include all consecutive
patients observed at the databank center.
We propose an international online registry for observa-
tional databanks similar to the metaRegister of Controlled
Trials (mRCT; http://www.controlled-trials.com/mrct/,
accessed 10 January 2004). All the databanks in such a
register should meet certain minimum methodological
standards such as those proposed by the Outcome Mea-
sures in Rheumatology (OMERACT). This register could
collate the data collection protocols and list of publica-
tions from each member databank and serve as a conve-
nient reference for publications. This register would also
help the users to be certain that they are aware of all the
observational evidence relevant to a particular question,
avoid duplication of effort, and encourage collaboration.
Patients who participate in databanks do so primarily on
the basis of altruism. Patients trust their physicians to use
their information for the greatest good of all others with
the same disease. Although researchers who obtain
funding and collect data deserve to have credit in terms of
primacy and publications, data more than, say, 5 years old
could very well be shared. Currently such informal data
sharing exists through academic networking but the
potential is probably not fully used. Research organiza-
tions such as the National Institutes of Health and the
Centers for Disease Control have placed large amounts of
data online, ready to be downloaded. There is little reason
why similar sharing of data from rheumatic disease data-
banks for non-commercial purposes could not be phased
in over time.
Medical journals have a key role in enforcing quality stan-
dards on reporting observational studies. Unfortunately,
journals do not explicitly insist on the guidelines such as
those by OMERACT. Providing checklists of reporting
requirements similar to the CONSORT (Consolidated
Standards of Reporting Trials) checklist for RCTs [14]
would streamline the reporting of drug effectiveness data
from observational studies.
Patient databanks are here to stay. Our plea here is for
methodologically sound observational studies to raise the
bar in the performance of clinical research.
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